Study of AMV564 in Subjects With Advanced Solid Tumors

Open to people ages 18 years and up

• 18 years of age or older
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Histologically or cytologically documented, incurable or metastatic solid tumor that is advanced (non-resectable) or recurrent and progressing since the last anti-tumor therapy and for which no recognized standard therapy exists
• Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or per other criteria best suited for the specific tumor type being evaluated
• Willing to complete all scheduled visits and assessments at the institution administering therapy

• Treatment with any local or systemic antineoplastic therapy (including chemotherapy, hormonal therapy, or radiation) within 3 weeks prior to first dose of AMV564
• Major trauma or major surgery within 4 weeks prior to first dose of AMV564
• Prior treatment with chimeric antigen receptor (CAR) T-cell therapy or T-cell engager therapy
• Chronic use of corticosteroids in excess of 10 mg daily of prednisone or equivalent within 4 weeks prior to first dose of AMV564
• Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1 except for alopecia
• Known, central nervous system (CNS) disease involvement, or prior history of National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Grade ≥ 3 drug-related CNS toxicity